Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Transl Proteom. 2014 Dec 1;4-5:18–24. doi: 10.1016/j.trprot.2014.10.001

Table 2. Study Characteristics and Measurements.

The p value in the table refers to all three groups being compared with each other. Pairwise comparisons are shown by the superscripts, and are explained in the footnote below.

Characteristic Non-Diabetic
Controls (n=8)

Group 1
Participants with
Diabetes
(n=11) Group 2
Participants with
Diabetes and CVD
(n=15) Group 3
p
(for
comparison)
Demographic profile
Sex 3 males, 5 females 4 males, 7 females 8 males, 7 females* 0.03
Race 6 Caucasians, 2 Hispanics 8 Caucasians, 2 Hispanics, 1 Asian 10 Caucasians, 5 Hispanics 0.24
Age (years) 48±13 56 ± 13 53 ± 12 0.38
Body mass index (kg/m2) 25±3 34 ± 6 39 ± 12* 0.005
Vital signs
Systolic blood pressure (mm Hg) 110±14 123 ± 12 132 ± 13* 0.002
Diastolic blood pressure (mm Hg) 76±8 77 ± 7 79 ± 11 0.71
Medications (# of participants)
Statins 0 0# 7* <0.001
Metformin 0 2 5 0.1
Insulin 0 2 2 0.2
Aspirin 0 1 7* 0.001*
Beta blockers 0 2 6* 0.002*
ACE inhibitors or ARBs 0 4 7* 0.003*
Biochemical profile
Fasting Glucose (mg/dL) 95± 12 142 ± 57# 202± 88* <0.001
OGTT (mg/dl) $ Fasting=93± 10

2 hour post=135 ± 31
Hemoglobin A1c (%) 5.1±0.27 7.6 ± 2.9# 8.4 ± 2.9* 0.009
Fasting Insulin (IU) 7 ± 3 12 ± 7 16 ± 13* 0.04*
HDL cholesterol (mg/dL) 70 ± 14 53 ± 16#^ 39 ± 8 * <0.001
LDL cholesterol (mg/dL) 117±31 125 ± 21 111 ± 43 0.67
Triglycerides (mg/dL) 116±87 146 ± 64 212 ± 138 0.11
C-reactive protein (mg/L) 4 ± 4 7 ± 5 13 ± 12 0.23
HDL Apolipoprotein A-I (mg/dL) 127.5±25 90 ± 40 84 ± 39* 0.029*
M148 oxidation relative ratio $$ 0.087±0.02 0.127 ± 0.037# 0.236 ± 0.084* <0.001
$

The results were not corrected for possible ex vivo oxidation of methionine

Values are means ± SD

ANOVA Group comparisons were followed by Tukey group-wise comparisons when the p for the three-comparison was <0.05:

*

, p<0.05 Type diabetics with CVD vs. non-diabetics;

#

, p<0.05 Type 2 diabetics without CVD vs. non-diabetics.

^

, p<0.05 Type diabetics with CVD vs. Type 2 diabetics without CVD

$

OGTTs were only performed in non-diabetic subjects

$$

The results were not corrected for possible ex vivo oxidation of methionine

M148 oxidation and HDL Apo A-I were the primary endpoint and the statistical significance was assessed at the 0.05 level. For the other measures, a p value of 0.005 or less was considered significant to adjust for multiple comparisons.

ACE: Angiotensin Converting Enzyme

ARB: Angiotensin Receptor Blocker